Alzamend Neuro, Inc. (ALZN)

Balance Sheet (Annual)

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year	2020	2019	2018
Cash & Equivalents	1.93	0.09	0.04
Short-Term Investments	0	0.1	0.21
Cash & Cash Equivalents	1.93	0.19	0.25
Cash Growth	909.03%	-23.06%	-
Other Current Assets	0.98	1.62	1.25
Total Current Assets	2.91	1.81	1.5
Total Assets	2.91	1.81	1.5
Accounts Payable	0.56	0.99	1.18
Current Debt	0.34	0	0
Total Current Liabilities	0.9	0.99	1.18
Total Liabilities	0.9	0.99	1.18
Total Debt	0.34	0	0
Common Stock	18.85	12.61	7.69
Retained Earnings	-16.83	-11.79	-7.38
Shareholders' Equity	2.01	0.82	0.32
Total Liabilities and Equity	2.91	1.81	1.5
Net Cash / Debt	1.59	0.19	0.25
Net Cash / Debt Growth	733.66%	-23.06%	-
Net Cash Per Share	0.02	0.00	0.00
Working Capital	2.01	0.82	0.32
Book Value Per Share	0.03	0.01	0.01

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).